CN1180776C - Ofloxacin eye ointment - Google Patents
Ofloxacin eye ointment Download PDFInfo
- Publication number
- CN1180776C CN1180776C CNB021535930A CN02153593A CN1180776C CN 1180776 C CN1180776 C CN 1180776C CN B021535930 A CNB021535930 A CN B021535930A CN 02153593 A CN02153593 A CN 02153593A CN 1180776 C CN1180776 C CN 1180776C
- Authority
- CN
- China
- Prior art keywords
- ofloxacin
- eyes
- gel type
- present
- castor oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229960001699 ofloxacin Drugs 0.000 title claims abstract description 43
- 239000003885 eye ointment Substances 0.000 title abstract description 17
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 13
- 239000004359 castor oil Substances 0.000 claims abstract description 11
- 235000019438 castor oil Nutrition 0.000 claims abstract description 11
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 11
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 9
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 9
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 238000005984 hydrogenation reaction Methods 0.000 claims description 10
- 239000006210 lotion Substances 0.000 claims description 10
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000004327 boric acid Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 208000035143 Bacterial infection Diseases 0.000 abstract description 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 2
- 229940012356 eye drops Drugs 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 229920002125 Sokalan® Polymers 0.000 abstract 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 abstract 1
- 208000010217 blepharitis Diseases 0.000 abstract 1
- 235000010338 boric acid Nutrition 0.000 abstract 1
- 229960002645 boric acid Drugs 0.000 abstract 1
- 229960001631 carbomer Drugs 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 abstract 1
- 208000008025 hordeolum Diseases 0.000 abstract 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 abstract 1
- 238000007910 systemic administration Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000013521 mastic Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Abstract
The present invention relates to gel type eye ointment (dicklor eye ointment) prepared from ofloxacin as a medicine effective component for the first time, which is applied to the bacterial infection treatment of ophthalmology and intends to increase the bioavailability of the effective components of medicine, and increase therapeutic effect and medication safety. The present invention realizes that ofloxacin is made into eye ointment for the first time, which not only solves the problem that eye drops are easily diluted by tears and the stay time in eyes is short, but also solves the problem that systemic administration therapeutic effect is not ideal. The present invention has the major technical content that ofloxacin, carbomer, boracic acid, hydrogenized and hardened castor oil, ethylparaben, propanediol and sodium hyaluronate are made into a stable, water soluble and transparent cream body; one layer of a poromeric reticular membrane is formed on the surface of each of a pair of eyes after the present invention is used; action is lasting. The present invention is principally used for treating bacterial conjunctivitis caused by sensitive bacteria, and ophthalmology diseases, such as blepharitis, hordeolum, dacryocyst eyes, tarsadenitis, etc.
Description
Technical field
---ofloxacin---makes the gel-type eye ointment first to the present invention relates to a kind of effective ingredient, is applied to the treatment of ophthalmology bacterial infection, but commodity enlightening sieve eye ointment by name.
Background technology
The ofloxacin ophthalmic preparation producing of report has at present: 0.3% ofloxacin eye drops, 0.3% ofloxacin eye ointment, the still production of gel-free type ofloxacin eye ointment.
Di Keluo is the trade name through the ofloxacin eye ointment of approval.
Summary of the invention
Big in order to overcome dosage, oral drugs are difficult to the deficiency by blood-eye barrier, invent a kind of gel for eye use, the ophthalmology topical, not only solved eye drop and easily diluted by tear, the defective that the ophthalmic time of staying is short, and use amount is few, improve the bioavailability of effective ingredient, increase curative effect and drug safety.
Technical scheme of the present invention is: the ofloxacin effective ingredient forms stable transparent mastic with card pool nurse gel-type vehicle and sodium hyaluronate solution, uses the back and forms the gas-pervious reticular membrane of one deck at the eye table, and effect is lasting.
Gel Type Ofloxacin Eyes Lotion is a single preparations of ephedrine, and its chemistry is by name: (±)-9-fluoro-2,3-dihydro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-oxo-7H-pyrido [1,2,3-de]-[1,4] benzoxazinyl-6-carboxylic acid gel for eye use; Common name: ofloxacin eye ointment; Trade name: but enlightening sieve eye ointment; English name: Loxacin Eye Gel; The Chinese phonetic alphabet: Yangfushaxing Yangao; Ofloxacin ingredient and main adjunct ingredient and the preparation of forming in following ratio that is applied to ophthalmology illness thereof: wherein containing ofloxacin by weight is 0.1-1.0%; Containing card pool nurse is 0-3.0%; Containing the hydrogenation hardened castor oil is 0-5.0%; Containing hyaluronate sodium is 0-0.2%.The ofloxacin effective ingredient mixes with an amount of water for injection under acid condition, grinds to form superfine powder; Respectively with sodium chloride, hydrogenation hardened castor oil, ethyl hydroxybenzoate, propylene glycol, stir, add water, heating makes whole dissolvings.Card pool nurse is swelled into aqueous solution, adds the right amount of boron processed with acid and becomes transparent emulsifiable paste, joins in the above-mentioned cooled ofloxacin aqueous solution, stirs, and continues cooling, adds hyaluronate sodium.It is transparent to be stirred to mastic, filters packing, packing (seeing accompanying drawing).In addition, substrate such as ofloxacin effective ingredient and hydroxypropyl methylcellulose series, methylcellulose series, polyvinyl alcohol series and polyvinylpyrrolidone all can form gel, and card pool nurse series substrate effect is best.Among the above-mentioned preparation technology, its core technology is: (pH=5.0-6.5) dissolving under (1) ofloxacin ingredient acid condition, (2) be to guarantee the transparent key of mastic with adjunct ingredient Hybrid Heating dissolving (temperature range 60-80 ℃), (3) card pool nurse swelling (concentration range 1.5-3.0%) is made transparent emulsifiable paste, and (4) hyaluronate sodium mixes with mastic.
Good effect of the present invention: the application of ofloxacin gel for eye use has following advantage: (1), lower than oral administration cost, oral every day, dosage was 300-600mg, and ofloxacin gel type eye ointment drug content is 0.3%, use the about 150-225mg of gel content every day, ofloxacin use amount every day is 0.75-1.25mg.(2), the ofloxacin eye ointment directly acts on the affected part, can play a role fully effectively, GI irritation and other side effect that can avoid oral drug therapy to bring.(3), with respect to other ophthalmic preparation, gel has unrivaled advantage, compares with eye drop, ofloxacin gel type eye ointment is difficult for being diluted by tear, within the eye the time of staying long, help the abundant absorption and the utilization of principal agent; Compare with the eye ointment of vaseline substrate, ofloxacin gel type eye ointment good water solubility, easy cleaning, pollution clothes is not easy to use.On the other hand, ofloxacin gel type eye ointment does not cause the visual field fuzzy, all can use round the clock.
Description of drawings
Fig. 1 is a Gel Type Ofloxacin Eyes Lotion preparation technology flow chart
The specific embodiment
Prescription 1:
Ofloxacin ... 0.3g card pool nurse ... 0.6g
Sodium chloride ... 0.5g boric acid ... 1.0g
The hydrogenation hardened castor oil ... 1.0g ethyl hydroxybenzoate ... 0.025g
Propylene glycol ... 1.0g hyaluronate sodium ... 0.05g
Make ... 100.0g
Operating process:
1.. the ofloxacin porphyrize, with sodium chloride, hydrogenation hardened castor oil, ethyl hydroxybenzoate, propylene glycol, stir, add water, heating makes whole dissolvings.
2.. boric acid, card are moored nurse, are stirred, in the adding 1..
3.. heating stirs.
4.. cooling below 40 ℃, adds hyaluronate sodium.
5.. filter, packing, packing, promptly.
Prescription 2:
Ofloxacin ... 0.1-1.0g card pool nurse ... 0.1-3.0g
Sodium chloride ... 0.1-1.0g boric acid ... 0.5-2.0g
The hydrogenation hardened castor oil ... 0.1-5.0g ethyl hydroxybenzoate ... 0.025-0.1g
Propylene glycol ... 0.5-5.0g hyaluronate sodium ... 0.01-0.1g
Make ... 100.0g
Operating process:
1.. the ofloxacin porphyrize, with sodium chloride, hydrogenation hardened castor oil, ethyl hydroxybenzoate, propylene glycol, stir, add water, heating makes whole dissolvings.
2.. boric acid, card are moored nurse, are stirred, in the adding 1..
3.. heating stirs.
4.. cooling below 40 ℃, adds hyaluronate sodium.
5.. filter, packing, packing, promptly.
Claims (5)
1 Gel Type Ofloxacin Eyes Lotion is characterized in that by weight, contains ofloxacin 0.1～1.0%, card pool nurse 0.1～3.0%, hydrogenation hardened castor oil 0.1～5.0%, hyaluronate sodium 0.01～0.2%.
2 Gel Type Ofloxacin Eyes Lotions according to claim 1, it is characterized in that, every 100g Gel Type Ofloxacin Eyes Lotion contains ofloxacin 0.1～1.0g, sodium chloride 0.1～1.0g, hydrogenation hardened castor oil 0.1～5.0g, propylene glycol 0.5～5.0g, card pool nurse 0.1～3.0g, boric acid 0.5～2.0g, ethyl hydroxybenzoate 0.025～0.1g, hyaluronate sodium 0.01～0.1g.
3 Gel Type Ofloxacin Eyes Lotions according to claim 1, it is characterized in that, every 100g Gel Type Ofloxacin Eyes Lotion contains ofloxacin 0.3g, sodium chloride 0.5g, hydrogenation hardened castor oil 1.0g, propylene glycol 1.0g, card pool nurse 0.6g, boric acid 1.0g, ethyl hydroxybenzoate 0.025g, hyaluronate sodium 0.05g.
The preparation method of the Gel Type Ofloxacin Eyes Lotion of 4 claim 1, be to mix with an amount of water for injection under 5.0～6.5 the acid condition ofloxacin at pH value, stir with sodium chloride, hydrogenation hardened castor oil, ethyl hydroxybenzoate, propylene glycol respectively, add water, heating-up temperature is 60～80 ℃ makes whole dissolvings; To block the pool nurse and be swelled into 1.5～3.0% aqueous solutions, and add boric acid and make transparent emulsifiable paste, and join in the above-mentioned ofloxacin aqueous solution, cooling adds sodium hyaluronate solution.
The application of the Gel Type Ofloxacin Eyes Lotion of 5 claim 1 in preparation treatment ophthalmology illness medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021535930A CN1180776C (en) | 2002-12-02 | 2002-12-02 | Ofloxacin eye ointment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021535930A CN1180776C (en) | 2002-12-02 | 2002-12-02 | Ofloxacin eye ointment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1437947A CN1437947A (en) | 2003-08-27 |
| CN1180776C true CN1180776C (en) | 2004-12-22 |
Family
ID=27672199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021535930A Expired - Lifetime CN1180776C (en) | 2002-12-02 | 2002-12-02 | Ofloxacin eye ointment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1180776C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009006130A2 (en) * | 2007-06-28 | 2009-01-08 | Bausch & Lomb Incorporated | Salt free hyaluronate ophthalmic solution |
| CN101618018B (en) * | 2008-07-01 | 2011-11-09 | 上海通用药业股份有限公司 | Miconazole nitrate particle, and preparation method and medicinal composition thereof |
| US9278132B2 (en) | 2012-02-13 | 2016-03-08 | Bausch & Lomb Incorporated | Ophthalmic pharmaceutical compositions and methods of making and using same |
| CN104523575B (en) * | 2014-12-24 | 2017-09-26 | 昆明振华制药厂有限公司 | A kind of hydrobenzole hydrochloride gel for eye and preparation method thereof |
-
2002
- 2002-12-02 CN CNB021535930A patent/CN1180776C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1437947A (en) | 2003-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078284B (en) | Gatifloxacin-containing gel for eyes and preparation method thereof | |
| CN101716214B (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| JP6644817B2 (en) | Topical dapsone and dapsone / adapalene compositions and methods of use | |
| CN101564374A (en) | Medicinal in situ forming eye gel | |
| AU6545301A (en) | Pharmaceutical composition for ophthalmic use | |
| TW201110961A (en) | Ophthalmic composition | |
| WO2009113910A1 (en) | Antiinflammatory and antiallergic gel | |
| CA2491341A1 (en) | Topical formulations for treatment of rosacea | |
| US20220142944A1 (en) | Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions | |
| CN101073556A (en) | Eyes preparation for divergent pupil and its making method | |
| CN1180776C (en) | Ofloxacin eye ointment | |
| CN109010375B (en) | Eye lotion | |
| CN1456350A (en) | Eye cyclosporin gel | |
| CN1456157A (en) | Ophthalmic gel of L-ofloxacin | |
| Palmer et al. | Tear film, pharmacology of eye drops, and toxicity | |
| JPH11189533A (en) | Eye drop | |
| CN1206988C (en) | Eye gel for atropine sulfate | |
| CN1843503A (en) | Eye drops | |
| CN100427091C (en) | Gatiflxacin eye gels based on HPMC medium and its preparing method | |
| CN1194685C (en) | Ophthalmic gel of marticarpine | |
| CN1879625A (en) | In situ-forming eye gel composition of ganciclovir and preparation method thereof | |
| CN1194686C (en) | Eye drops of fluconazole | |
| CN111588693B (en) | Cromolyn sodium eye drops and preparation method thereof | |
| CN114452292B (en) | Application of pulsatilla saponin B4 in preparation of skin care products | |
| CN1943598A (en) | Eye medicine for preventing and curing shortsightedness and relieving sight fatigue and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd. Assignor: Liu Jidong Contract fulfillment period: 2008.9.29 to 2013.9.29 Contract record no.: 2008210000056 Denomination of invention: Ofloxacin eye ointment Granted publication date: 20041222 License type: Exclusive license Record date: 20081105 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.9.29 TO 2013.9.29; CHANGE OF CONTRACT Name of requester: SHENYANG XING QI PHARMACEUTICAL CO., LTD. Effective date: 20081105 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd. Assignor: Liu Jidong Contract fulfillment period: 2008.9.29 to 2013.9.29 Contract record no.: 2008210000056 Denomination of invention: Ofloxacin eye ointment Granted publication date: 20041222 License type: Exclusive license Record date: 20081105 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.9.29 TO 2013.9.29; CHANGE OF CONTRACT Name of requester: SHENYANG XING QI PHARMACEUTICAL CO., LTD. Effective date: 20081105 |
|
| ASS | Succession or assignment of patent right |
Owner name: SHENYANG XINGQI MEDICINE CO., LTD. Free format text: FORMER OWNER: LIU JIDONG Effective date: 20111013 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20111013 Address after: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee after: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd. Address before: 110027 -4, No. 12, 3 Street, Shenyang economic and Technological Development Zone, Liaoning, Shenyang Patentee before: Liu Jidong |
|
| C56 | Change in the name or address of the patentee |
Owner name: SHENYANG SINQI EYE PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHENYANG XINGQI MEDICINE CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 110024, 4, 12, three street, Shenyang economic and Technological Development Zone Patentee after: SHENYANG XINGQI PHARMACEUTICAL Co.,Ltd. Address before: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee before: SHENYANG SINQI PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20041222 |
|
| CX01 | Expiry of patent term |